Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Novo Nordisk ADR (NYSE: NVO) closed the day trading at $50.9 up 2.25% from the previous closing price of $49.78. In other words, the price has increased by $2.25 from its previous closing price. On the day, 19.38 million shares were traded. NVO stock price reached its highest trading level at $51.235 during the session, while it also had its lowest trading level at $50.25.
Ratios:
For a better understanding of NVO, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 57.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.06. For the most recent quarter (mrq), Quick Ratio is recorded 0.56 and its Current Ratio is at 0.78. In the meantime, Its Debt-to-Equity ratio is 0.59 whereas as Long-Term Debt/Eq ratio is at 0.52.
HSBC Securities Downgraded its Buy to Hold on July 31, 2025, while the target price for the stock was maintained at $57.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 30 ’25 when Novo Nordisk A/S bought 921,897 shares for $2.14 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 226638348288 and an Enterprise Value of 301527957504. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.02, and their Forward P/E ratio for the next fiscal year is 11.98. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.03. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.77 while its Price-to-Book (P/B) ratio in mrq is 8.55. Its current Enterprise Value per Revenue stands at 0.967 whereas that against EBITDA is 1.893.
Stock Price History:
The Beta on a monthly basis for NVO is 0.65, which has changed by -0.63000655 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, NVO has reached a high of $139.74, while it has fallen to a 52-week low of $45.05. The 50-Day Moving Average of the stock is -22.67%, while the 200-Day Moving Average is calculated to be -36.34%.
Shares Statistics:
Over the past 3-months, NVO traded about 14.22M shares per day on average, while over the past 10 days, NVO traded about 27545570 shares per day. A total of 3.37B shares are outstanding, with a floating share count of 3.37B. Insiders hold about 0.00% of the company’s shares, while institutions hold 9.56% stake in the company. Shares short for NVO as of 1753920000 were 20756474 with a Short Ratio of 1.46, compared to 1751241600 on 25701254. Therefore, it implies a Short% of Shares Outstanding of 20756474 and a Short% of Float of 0.62.
Dividends & Splits
NVO’s forward annual dividend rate is 1.66, up from 11.65 a year ago. Against a Trailing Annual Dividend Yield of 0.23402973The stock’s 5-year Average Dividend Yield is 1.49. The current Payout Ratio is 35.93% for NVO, which recently paid a dividend on 2025-03-31 with an ex-dividend date of 2025-03-31. Stock splits for the company last occurred on 2023-09-20 when the company split stock in a 2:1 ratio.
Earnings Estimates
As of right now, 4.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $6.03, with high estimates of $6.49 and low estimates of $5.69.
Analysts are recommending an EPS of between $24.9 and $23.81 for the fiscal current year, implying an average EPS of $24.52. EPS for the following year is $26.18, with 7.0 analysts recommending between $29.89 and $24.14.
Revenue Estimates
9 analysts predict $78.31B in revenue for the current quarter. It ranges from a high estimate of $85.77B to a low estimate of $74.03B. As of the current estimate, Novo Nordisk ADR’s year-ago sales were $71.31BFor the next quarter, 9 analysts are estimating revenue of $84.71B. There is a high estimate of $99.99B for the next quarter, whereas the lowest estimate is $79.59B.
A total of 22 analysts have provided revenue estimates for NVO’s current fiscal year. The highest revenue estimate was $353.05B, while the lowest revenue estimate was $309.51B, resulting in an average revenue estimate of $320.7B. In the same quarter a year ago, actual revenue was $290.4BBased on 22 analysts’ estimates, the company’s revenue will be $350.97B in the next fiscal year. The high estimate is $405.13B and the low estimate is $317.52B.
